<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02914509</url>
  </required_header>
  <id_info>
    <org_study_id>OTX-16-002</org_study_id>
    <nct_id>NCT02914509</nct_id>
  </id_info>
  <brief_title>Phase 3 Study Evaluating Safety and Efficacy of OTX-TP in Subjects With OAG or OHT</brief_title>
  <official_title>A Prospective, Multicenter, Randomized, Parallel-Arm, Double Masked, Vehicle Controlled Phase 3A Study Evaluating the Safety and Efficacy of OTX-TP in the Treatment of Subjects With Open-Angle Glaucoma or Ocular Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ocular Therapeutix, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ocular Therapeutix, Inc.</source>
  <brief_summary>
    <textblock>
      The objective of the study is to evaluate evaluate the safety and IOP lowering efficacy of&#xD;
      OTX-TP, a sustained release travoprost drug product, placed in the canaliculus of the eyelid&#xD;
      in the treatment of subjects with open-angle glaucoma or ocular hypertension&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a prospective, multicenter, randomized, parallel-arm, double masked, placebo vehicle&#xD;
      (PV) controlled study conducted to evaluate the safety and IOP-lowering efficacy of OTX-TP, a&#xD;
      sustained release drug product placed in the canaliculus of the eyelid in subjects with&#xD;
      open-angle glaucoma or ocular hypertension. A total of up to 550 subjects (1100 eyes) with a&#xD;
      clinical diagnosis of open-angle glaucoma or ocular hypertension in both eyes received either&#xD;
      OTX-TP or PV to evaluate the safety and efficacy of OTX-TP.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 7, 2016</start_date>
  <completion_date type="Actual">March 30, 2019</completion_date>
  <primary_completion_date type="Actual">March 30, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean IOP</measure>
    <time_frame>Mean IOP at 8AM, 10AM, and 4PM at the 2 Week Visit</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean IOP</measure>
    <time_frame>Mean IOP at 8AM, 10AM, and 4PM at the 6 Week Visit</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean IOP</measure>
    <time_frame>Mean IOP at 8AM, 10AM, and 4PM at the 12 Week Visit</time_frame>
  </primary_outcome>
  <other_outcome>
    <measure>Number of Participants With Serious Adverse Events</measure>
    <time_frame>Through study completion, an average of 23 months</time_frame>
    <description>Number of Participants with Serious Adverse Events</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">565</enrollment>
  <condition>Open Angle Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>OTX-TP (sustained release travoprost) Intracanalicular Depot</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OTX-TP (sustained release travoprost) Intracanalicular Depot</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PV (Placebo Vehicle) Intracanalicular Depot</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PV (Placebo Vehicle) Intracanalicular Depot</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Travoprost</intervention_name>
    <arm_group_label>OTX-TP (sustained release travoprost) Intracanalicular Depot</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Vehicle</intervention_name>
    <arm_group_label>PV (Placebo Vehicle) Intracanalicular Depot</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Documented diagnosis of ocular hypertension with an open angle of Schaffer Grade 3 or&#xD;
             greater or open-angle glaucoma without pseudoexfoliation or pigment dispersion or&#xD;
             evidence of traumatic angle recession&#xD;
&#xD;
          -  IOP is currently controlled as assessed by the Investigator&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Punctum size smaller than 0.4 mm or greater than 0.9 mm in either eye as measured&#xD;
             using a standard punctum gauge&#xD;
&#xD;
          -  A history of an inadequate response or no response to topical prostaglandin&#xD;
&#xD;
          -  Known or suspected allergy and/or hypersensitivity to travoprost or any prostaglandin,&#xD;
             fluorescein, or to any component of the study products&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Artesia</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lakeland</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Morrow</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shawnee Mission</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Des Peres</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 21, 2016</study_first_submitted>
  <study_first_submitted_qc>September 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2016</study_first_posted>
  <results_first_submitted>April 29, 2021</results_first_submitted>
  <results_first_submitted_qc>September 14, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 11, 2021</results_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Travoprost</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 2, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/09/NCT02914509/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 2, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/09/NCT02914509/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>OTX-TP</title>
          <description>Three forty eight (348) subjects were randomized to OTX-TP</description>
        </group>
        <group group_id="P2">
          <title>Placebo Vehicle (PV)</title>
          <description>Two hundred seventeen (217) subjects were randomized to the PV.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="348"/>
                <participants group_id="P2" count="217"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="343"/>
                <participants group_id="P2" count="211"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>OTX-TP (Sustained Release Travoprost) Intracanalicular Depot</title>
          <description>Three hundred forty eight (348) subjects were randomized to OTX-TP</description>
        </group>
        <group group_id="B2">
          <title>Placebo Vehicle (PV)</title>
          <description>Two hundred seventeen (217) subjects were randomized to the PV.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="348"/>
            <count group_id="B2" value="217"/>
            <count group_id="B3" value="565"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="160"/>
                    <measurement group_id="B2" value="91"/>
                    <measurement group_id="B3" value="251"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="188"/>
                    <measurement group_id="B2" value="126"/>
                    <measurement group_id="B3" value="314"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65" spread="11"/>
                    <measurement group_id="B2" value="65" spread="11"/>
                    <measurement group_id="B3" value="65" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="185"/>
                    <measurement group_id="B2" value="135"/>
                    <measurement group_id="B3" value="320"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="163"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="247"/>
                    <measurement group_id="B2" value="159"/>
                    <measurement group_id="B3" value="406"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="348"/>
                    <measurement group_id="B2" value="217"/>
                    <measurement group_id="B3" value="565"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean IOP</title>
        <time_frame>Mean IOP at 8AM, 10AM, and 4PM at the 2 Week Visit</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OTX-TP (Sustained Release Travoprost) Intracanalicular Depot</title>
            <description>Three hundred forty eight (348) subjects were randomized to OTX-TP</description>
          </group>
          <group group_id="O2">
            <title>Placebo Vehicle (PV)</title>
            <description>Two hundred seventeen (217) subjects were randomized to the PV.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean IOP</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="343"/>
                <count group_id="O2" value="211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>8AM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21" spread="0.2"/>
                    <measurement group_id="O2" value="22.9" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10AM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.2" spread="0.2"/>
                    <measurement group_id="O2" value="21.9" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4PM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.5" spread="0.2"/>
                    <measurement group_id="O2" value="21.5" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean IOP</title>
        <time_frame>Mean IOP at 8AM, 10AM, and 4PM at the 6 Week Visit</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OTX-TP (Sustained Release Travoprost) Intracanalicular Depot</title>
            <description>Three hundred forty eight (343) subjects were randomized to OTX-TP</description>
          </group>
          <group group_id="O2">
            <title>Placebo Vehicle (PV)</title>
            <description>Two hundred seventeen (211) subjects were randomized to the PV.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean IOP</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="343"/>
                <count group_id="O2" value="211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>8AM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.9" spread="0.2"/>
                    <measurement group_id="O2" value="26.9" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10AM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.1" spread="0.2"/>
                    <measurement group_id="O2" value="25" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4PM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.8" spread="0.2"/>
                    <measurement group_id="O2" value="24.6" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean IOP</title>
        <time_frame>Mean IOP at 8AM, 10AM, and 4PM at the 12 Week Visit</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OTX-TP (Sustained Release Travoprost) Intracanalicular Depot</title>
            <description>Three hundred forty eight (343) subjects were randomized to OTX-TP</description>
          </group>
          <group group_id="O2">
            <title>Placebo Vehicle (PV)</title>
            <description>Two hundred seventeen (211) subjects were randomized to the PV.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean IOP</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="343"/>
                <count group_id="O2" value="211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>8AM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.8" spread="0.2"/>
                    <measurement group_id="O2" value="23.2" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10AM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.7" spread="0.2"/>
                    <measurement group_id="O2" value="22.5" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4PM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.4" spread="0.2"/>
                    <measurement group_id="O2" value="22.1" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Serious Adverse Events</title>
        <description>Number of Participants with Serious Adverse Events</description>
        <time_frame>Through study completion, an average of 23 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OTX-TP (Sustained Release Travoprost) Intracanalicular Depot</title>
            <description>Three hundred forty eight (348) subjects were randomized to OTX-TP</description>
          </group>
          <group group_id="O2">
            <title>Placebo Vehicle (PV)</title>
            <description>Two hundred seventeen (217) subjects were randomized to the PV.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious Adverse Events</title>
          <description>Number of Participants with Serious Adverse Events</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="348"/>
                <count group_id="O2" value="217"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>through study duration, an average of 23 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>OTX-TP (Sustained Release Travoprost) Intracanalicular Depot</title>
          <description>Three hundred forty eight (348) subjects were randomized to OTX-TP</description>
        </group>
        <group group_id="E2">
          <title>Placebo Vehicle (PV)</title>
          <description>Two hundred seventeen (217) subjects were randomized to the PV.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="348"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="217"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Serious Adverse Event</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="217"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Serious Adverse Events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="217"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Serious Adverse Event</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="217"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Serious Adverse Event</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="217"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Serious Adverse Event</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="217"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Serious Adverse Event</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="348"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="217"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Serious Adverse Event</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="217"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Serious Adverse Event</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="217"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Serious Adverse Event</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="217"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="132" subjects_at_risk="348"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="217"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse Event</sub_title>
                <counts group_id="E1" subjects_affected="132" subjects_at_risk="348"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="217"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Project Manager</name_or_title>
      <organization>Ocular Therapeutix, Inc.</organization>
      <phone>781-357-4000</phone>
      <email>clinicalaffairs@ocutx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

